Serum–Glucocorticoid Regulated Kinase 1 Regulates Macrophage Recruitment and Activation Contributing to Monocrotaline-Induced Pulmonary Arterial Hypertension

Cardiovascular Toxicology

Volumn 14, Issue 4, 2014, Pages 368-378

  Xi, Xin ^a,b,c   Liu, Shuang ^a,b,c   Shi, Hongtao ^a,b,c   Yang, Min ^a,b,c   Qi, Yongfen ^a,b,c   Wang, Jian ^d   Du, Jie ^a,b,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE OF HEART   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Macrophage; Pulmonary arterial hypertension; Pulmonary arterial smooth muscle cell; Serum glucocorticoid regulated kinase 1

Indexed keywords

IMMEDIATE EARLY PROTEIN; MESSENGER RNA; MONOCROTALINE; PROTEIN SERINE THREONINE KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE;

ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; VASCULAR REMODELING;

ANIMALS; HYPERTENSION, PULMONARY; IMMEDIATE-EARLY PROTEINS; INFLAMMATION; MACROPHAGES; MICE; MICE, KNOCKOUT; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; PROTEIN-SERINE-THREONINE KINASES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; VASCULAR REMODELING;

EID: 84936773583     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-014-9260-4     Document Type: Article

References (40)

1. Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011). Mechanisms of disease: pulmonary arterial hypertension. Nature Review Cardiology,8, 443–455.
2. Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J. L., et al. (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal,34, 1219–1263.
3. Galie, N., Palazzini, M., & Manes, A. (2010). Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. European Heart Journal,31, 2080–2086.
4. Wilkins, M. R. (2012). Pulmonary hypertension: the science behind the disease spectrum. European Respiratory Reviews,21, 19–26.
5. Stacher, E., Graham, B. B., Hunt, J. M., Gandjeva, A., Groshong, S. D., et al. (2012). Modern age pathology of pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine,186, 261–272.
6. Morrell, N. W., Adnot, S., Archer, S. L., Dupuis, J., Jones, P. L., et al. (2009). Cellular and molecular basis of pulmonary arterial hypertension. Journal of the American College of Cardiology,54, S20–S31.
7. Archer, S. L., Weir, E. K., & Wilkins, M. R. (2010). Basic science of pulmonary arterial hypertension for clinicians: New concepts and experimental therapies. Circulation,121, 2045–2066.
8. El Chami, H., & Hassoun, P. M. (2012). Immune and inflammatory mechanisms in pulmonary arterial hypertension. Progress in Cardiovascular Diseases,55, 218–228.
9. Marsboom, G., Toth, P. T., Ryan, J. J., Hong, Z., Wu, X., et al. (2012). Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circulation Research,110, 1484–1497.
10. Savai, R., Pullamsetti, S. S., Kolbe, J., Bieniek, E., Voswinckel, R., et al. (2012). Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine,186, 897–908.
11. Burke, D. L., Frid, M. G., Kunrath, C. L., Karoor, V., Anwar, A., et al. (2009). Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. American Journal of Physiology. Lung Cellular and Molecular Physiology,297, L238–L250.
12. Gomez-Arroyo, J. G., Farkas, L., Alhussaini, A. A., Farkas, D., Kraskauskas, D., et al. (2012). The monocrotaline model of pulmonary hypertension in perspective. American Journal of Physiology. Lung Cellular and Molecular Physiology,302, L363–L369.
13. Pinto, R. F., Higuchi Mde, L., & Aiello, V. D. (2004). Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. Cardiovascular Pathology,13, 268–275.
14. Vergadi, E., Chang, M. S., Lee, C., Liang, O. D., Liu, X., et al. (2011). Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation,123, 1986–1995.
15. Sahara, M., Sata, M., Morita, T., Nakamura, K., Hirata, Y., et al. (2007). Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation. Circulation,115, 509–517.
16. Tian, W., Jiang, X., Tamosiuniene, R., Sung, Y. K., Qian, J., et al. (2013). Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Science Translational Medicine,5, 200ra117.
17. Talati, M., West, J., Blackwell, T. R., Loyd, J. E., & Meyrick, B. (2010). BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology,299, L363–L373.
18. Frid, M. G., Brunetti, J. A., Burke, D. L., Carpenter, T. C., Davie, N. J., et al. (2006). Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. American Journal of Pathology,168, 659–669.
19. Chung, J. H., Jeon, H. J., Hong, S. Y., da Lee, L., Lee, K. H., et al. (2012). Palmitate promotes the paracrine effects of macrophages on vascular smooth muscle cells: The role of bone morphogenetic proteins. PLoS ONE,7, e29100.
20. Lee, M. J., Kim, M. Y., Heo, S. C., Kwon, Y. W., Kim, Y. M., et al. (2012). Macrophages regulate smooth muscle differentiation of mesenchymal stem cells via a prostaglandin F(2)alpha-mediated paracrine mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology,32, 2733–2740.
21. Webster, M. K., Goya, L., Ge, Y., Maiyar, A. C., & Firestone, G. L. (1993). Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Molecular and Cellular Biology,13, 2031–2040.
22. Lang, F., Artunc, F., & Vallon, V. (2009). The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. Current Opinion in Nephrology and Hypertension,18, 439–448.
23. Cheng, J., Wang, Y., Ma, Y., Chan, B. T., Yang, M., et al. (2010). The mechanical stress-activated serum-, glucocorticoid-regulated kinase 1 contributes to neointima formation in vein grafts. Circulation Research,107, 1265–1274.
24. Yang, M., Zheng, J., Miao, Y., Wang, Y., Cui, W., et al. (2012). Serum–glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology,32, 1675–1686.
25. BelAiba, R. S., Djordjevic, T., Bonello, S., Artunc, F., Lang, F., et al. (2006). The serum- and glucocorticoid-inducible kinase Sgk-1 is involved in pulmonary vascular remodeling: Role in redox-sensitive regulation of tissue factor by thrombin. Circulation Research,98, 828–836.
26. Ackermann, T. F., Boini, K. M., Beier, N., Scholz, W., Fuchss, T., et al. (2011). EMD638683, a novel SGK inhibitor with antihypertensive potency. Cellular Physiology and Biochemistry,28, 137–146.
27. Schermuly, R. T., Dony, E., Ghofrani, H. A., Pullamsetti, S., Savai, R., et al. (2005). Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation,115, 2811–2821.
28. Yamazato, Y., Ferreira, A. J., Hong, K. H., Sriramula, S., Francis, J., et al. (2009). Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension,54, 365–371.
29. Wang, J., Jiang, Q., Wan, L., Yang, K., Zhang, Y., et al. (2013). Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. American Journal of Respiratory Cell and Molecular Biology,48, 125–134.
30. Li, Y., Zhang, C., Wu, Y., Han, Y., Cui, W., et al. (2012). Interleukin-12p35 deletion promotes CD4 T-cell-dependent macrophage differentiation and enhances angiotensin II-Induced cardiac fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology,32, 1662–1674.
31. Zhang, Y., Wang, Y., Liu, Y., Wang, N., Qi, Y., et al. (2013). Kruppel-like factor 4 transcriptionally regulates TGF-beta1 and contributes to cardiac myofibroblast differentiation. PLoS ONE,8, e63424.
32. Price, L. C., Wort, S. J., Perros, F., Dorfmuller, P., Huertas, A., et al. (2012). Inflammation in pulmonary arterial hypertension. Chest,141, 210–221.
33. Meng, F., Yamagiwa, Y., Taffetani, S., Han, J., & Patel, T. (2005). IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway. American Journal of Physiology. Cell Physiology,289, C971–C981.
34. Saad, S., Agapiou, D. J., Chen, X. M., Stevens, V., & Pollock, C. A. (2009). The role of Sgk-1 in the upregulation of transport proteins by PPAR-(gamma) agonists in human proximal tubule cells. Nephrology, Dialysis, Transplantation,24, 1130–1141.
35. Waerntges, S., Klingel, K., Weigert, C., Fillon, S., Buck, M., et al. (2002). Excessive transcription of the human serum and glucocorticoid dependent kinase hSGK1 in lung fibrosis. Cellular Physiology and Biochemistry,12, 135–142.
36. Voelkl, J., Pasham, V., Ahmed, M. S., Walker, B., Szteyn, K., et al. (2013). Sgk1-dependent stimulation of cardiac Na+/H+ exchanger Nhe1 by dexamethasone. Cellular Physiology and Biochemistry,32, 25–38.
37. Towhid, S. T., Liu, G. L., Ackermann, T. F., Beier, N., Scholz, W., et al. (2013). Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cellular Physiology and Biochemistry,32, 838–848.
38. Liu, G., Alzoubi, K., Umbach, A. T., Pelzl, L., Borst, O., et al. (2014). Upregulation of store operated ca channel orai1, stimulation of Ca entry and triggering of cell membrane scrambling in platelets by mineralocorticoid DOCA. Kidney and Blood Pressure Research,38, 21–30.
39. Lang, F., Bohmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., et al. (2006). (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiological Reviews,86, 1151–1178.
40. Zhang, L., Cui, R., Cheng, X., & Du, J. (2005). Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I[kgr]B kinase. Cancer Research,65, 457–464.